$734 25.5 3.6%
Last Trade - 15/01/21
| Market Cap | ÂŁ946.8m |
| Enterprise Value | ÂŁ915.6m |
| Revenue | ÂŁ109.5m |
| Position in Universe | 2418th / 6543 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 140.8 | 145.7 | 143.5 | 146.6 | 152.4 | 155.1 | +2.0% | ||||
| +6.8 | +9.9 | -4.0 | +20.2 | +3.3 | +7.0 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company's medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | December 30, 1996 |
| Public Since | December 13, 1995 |
| No. of Shareholders: | 8,200 |
| No. of Employees: | 616 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 1,828,953 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 1 Allentown Pkwy, ALLEN, 75002-4206, United States |
| Web | http://www.atrioncorp.com/ |
| Phone | +1 972 3909800 |
| Contact | Jeffery Strickland (Chief Financial Officer, Vice President, Treasurer, Secretary) |
| Auditors | Grant Thornton LLP |
As of 15/01/21, shares in Atrion are trading at $734, giving the company a market capitalisation of ÂŁ946.8m. This share price information is delayed by 15 minutes.
Shares in Atrion are currently trading at $734 and the price has moved by 1.22% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Atrion price has moved by -11.88% over the past year.
Of the analysts with advisory recommendations for Atrion, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Atrion is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Atrion is scheduled to issue upcoming financial results on the following dates:
The Atrion dividend yield is 0.9% based on the trailing twelve month period.
Last year, Atrion paid a total dividend of 6.4, and it currently has a trailing dividend yield of 0.9%. Looking ahead, Atrion has not announced an ex-dividend date yet.
Atrion has yet to annouce their ex-dividend date. The historic dividend yield on Atrion shares is currently 0.9%.
To buy shares in Atrion you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Atrion are currently trading at $734, giving the company a market capitalisation of ÂŁ946.8m.
Here are the trading details for Atrion:
Based on an overall assessment of its quality, value and momentum, Atrion is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Atrion are currently priced at $734. At that level they are trading at 57.66% premium to the analyst consensus target price of 0.00.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atrion. Over the past six months, the relative strength of its shares against the market has been -9.37%. At the current price of $734, shares in Atrion are trading at 10.47% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Atrion PE ratio based on its reported earnings over the past 12 months is 39.95. The shares are currently trading at $734.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Atrion's management team is headed by:
Here are the top five shareholders of Atrion based on the size of their shareholding:
